Oryzon to Present its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston
Drugs from ORYZON shown to be efficacious in the treatment of Acute Leukemia
Oryzon to attend BIO-Europe Spring 2012 Conference in Amsterdam
Oryzon participates in a R&D European consortium in Parkinson’s disease
Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
Contact
Oryzon Genomics Sant Ferran 74 08940 Cornellà de Llobregat, Barcelona SPAIN T: (+34) 93 515 1313 F: (+34) 93 377 4028 info@oryzon.com Access to R & D headquarters of ORYZON Buses 67, 68, 93 y 95 Metro Line 5 More information Ferrocarrils de la Generalitat de Catalunya – Almeda station Five minutes from El Prat International airport Next to the exit number 15 of the Ronda de Dalt and 16A of Ronda Litoral
Contact form